N-RAS AND K-RAS ONCOGENES IN PLASMA-CELL DYSCRASIAS

被引：23

作者：

CORRADINI, P

LADETTO, M

INGHIRAMI, G

BOCCADORO, M

PILERI, A

机构：

[1] Department of Medicine and Experimental Oncology Division of Hematology, University of Torino

[2] Department of Pathology, New York University

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 15卷 / 1-2期

关键词：

RAS ONCOGENES; PLASMA CELL LEUKEMIA; MULTIPLE MYELOMA; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE;

D O I：

10.3109/10428199409051673

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

N- and K-ras oncogene mutations represent the most frequent molecular lesions in plasma cell dyscrasias. They are not randomly distributed since they are detectable in multiple myeloma (MM) (9-31%) and plasma cell leukemia (PCL) (30%), and not in monoclonal gammopathy of undetermined significance (MGUS) and solitary plasmacytoma (SP). Codons 12, 13 and 61 of N- and K-ras genes have been found mutated. Mutations affecting codon 61 of N-ras gene are the most frequent finding. A heterogeneous pattern of mutations is described with a prevalence of purine-pyrimidine transversions. Ras gene mutations have been predominantly detected in myelomas characterized by an advanced stage disease, and adverse prognostic parameters. These findings suggest that ras mutations represent a late molecular lesion and may be implicated in tumor progression rather than tumor initiation.

引用

页码：17 / 20

页数：4

共 30 条

[1]

Kyle R.A., Diagnostic criteria of multiple myeloma, Hematol. Oncol. Clin. N. Am., 6, pp. 347-358, (1992)

[2]

Knowling M.A., Haarwood A.R., Bergsagel D.E., Comparison of extramedullar plasmacytomas with solitary and multiple plasma cell tumors of the bone, J. Clin. Oncol., 1, pp. 255-262, (1983)

[3]

Barlogie B., Epstein J., Selvanayagam P., Alexanian R., Plasma cell myeloma-new biological insights and advances in therapy, Blood, 73, pp. 865-879, (1988)

[4]

Ladanyi Feiner M., Niesvizky H.R., Michaeli J., Protoncogene analysis in multiple myeloma, Blood, 78, (1991)

[5]

Palumbo A.P., Boccadoro M., Battaglio S., Corradini P., Tsichlis P.N., Huebner K., Pileri A., Croce C.M., Human homologous of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3′ of the c-myc gene, is rearranged in multiple myeloma, Cancer Res., 50, pp. 6478-6482, (1990)

[6]

Selvanayagam P., Blick M., Nami F., van Tuinen P., Ledbetter D.H., Alexanian R., Saunders G.F., Barlogie B., Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma, Blood, 71, pp. 30-35, (1988)

[7]

Neri A., Murphy J.P., Cro L., Ferrero D., Tarella C., Baldini L., Dalla Favera R., Ras oncogene mutation in multiple myeloma, J. Exp. Med., 170, pp. 1715-1725, (1989)

[8]

Paquette R.L., Berenson J., Lichtenstein A., McCormick F., Koeffler H.P., Oncogenes in multiple myeloma: point mutations of N-ras, Oncogene, 5, pp. 1659-1663, (1990)

[9]

Corradini P., Ladetto M., Voena C., Palumbo A., Inghirami G., Knowles D.M., Boccadoro M., Pileri A., Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias, Blood, 81, pp. 2708-2713, (1993)

[10]

Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A.T., p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy, Blood, 81, pp. 128-135, (1993)

← 1 2 3 →